Market Overview

NIH Selects CEL-SCI's LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program


CEL-SCI Corporation (NYSE:CVM) announced today that the
National Institutes of Health (NIH) selected CEL-SCI and its LEAPS*
rheumatoid arthritis vaccine candidate as a Small Business Innovation
Research/Small Business Technology Transfer (SBIR/STTR)
Commercialization Accelerator Program Phase II awardee for 2018-2019.
LEAPS has been specifically selected by the NIH for the
Commercialization Transition Track, which provides technical assistance
to awardee companies to move NIH-funded technologies towards
commercialization and market readiness.

CEL-SCI was eligible and applied for the Commercialization Accelerator
Program as part of its $1.5
Phase II SBIR/STTR NIH grant to develop its LEAPS rheumatoid
arthritis vaccine. Only a select number of the SBIR Phase II awarded
companies are also accepted into the Commercialization Accelerator
Program by the NIH.

"We are pleased that the NIH has selected CEL-SCI and our LEAPS
rheumatoid arthritis vaccine candidate for this important
commercialization program. We believe the NIH's program will support and
accelerate LEAPS's advancement into clinical studies and towards
commercialization. Preclinical data have shown that LEAPS vaccines may
be advantageous to other therapies because LEAPS acts early on the
immune system to inhibit the production of disease-promoting
inflammatory cytokines," stated Dr. Daniel Zimmerman, Senior Vice
President of Research, Cellular Immunology of CEL-SCI.

About Rheumatoid Arthritis

Rheumatoid Arthritis is a chronic inflammatory disease that mainly
targets the synovial membrane, cartilage and bone. It affects about 1%
of the global population and is associated with significant morbidity
and increased mortality. Anti-TNF related therapies are the current
standard treatment of patients with advanced RA, but over half of the RA
patients do not respond well to current anti-TNF drugs such as
etanercept (Enbrel®) and infliximab (Remicade®).

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient's immune system while it is
still intact should provide the greatest possible impact on survival.
Therefore, in the Phase 3 study CEL-SCI treats patients who are newly
diagnosed with advanced primary squamous cell carcinoma of the head and
neck with Multikine** right after diagnosis, BEFORE they receive
surgery, radiation and/or chemotherapy. This approach is unique. Most
other cancer immunotherapies are administered only after conventional
therapies have been tried and/or failed. Multikine (Leukocyte
Interleukin, Injection), has received Orphan Drug designation from the
FDA for the neoadjuvant therapy in patients with squamous cell carcinoma
(cancer) of the head and neck.

CEL-SCI's Phase 3 study is the largest Phase 3 study in the world for
the treatment of head and neck cancer. Per the study's protocol, newly
diagnosed patients with advanced primary squamous cell carcinoma are
treated with the Multikine treatment regimen for 3 weeks prior to the
Standard of Care (SOC) which involves surgery, chemotherapy and/or
radiation. Multikine is designed to help the immune system "see" the
tumor at a time when the immune system is still relatively intact and
thereby better able to mount an attack on the tumor. The aim of
treatment with Multikine is to boost the body's immune system prior to

The Company's LEAPS technology is currently being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by grants
from the National Institutes of Health. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. When
used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements are
subject to risks and uncertainties that could cause actual results to
differ materially from those projected. Such statements include, but are
not limited to, statements about the terms, expected proceeds, use of
proceeds and closing of the offering. Factors that could cause or
contribute to such differences include, an inability to duplicate the
clinical results demonstrated in clinical studies, timely development of
any potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in manufacturing
any of the Company's potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission, including
but not limited to its report on Form 10-K for the year ended September
30, 2017. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

* LEAPS is an investigational technology, currently in preclinical
development. LEAPS has not been licensed or approved for sale, barter or
exchange anywhere in the world.

** Multikine (Leukocyte Interleukin, Injection) is the trademark that
CEL-SCI has registered for this investigational therapy, and this
proprietary name is subject to FDA review in connection with the
Company's future anticipated regulatory submission for approval.
Multikine has not been licensed or approved for sale, barter or exchange
by the FDA or any other regulatory agency. Similarly, its safety or
efficacy has not been established for any use. Moreover, no definitive
conclusions can be drawn from the early-phase, clinical-trials data
involving the investigational therapy Multikine. Further research is
required, and early-phase clinical trial results must be confirmed in
the Phase 3 clinical trial of this investigational therapy that is in

View Comments and Join the Discussion!